fbx-101
Gene therapyexperimental
Clinical trial activity
2 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
2
Phase 3
0
Phase 4
0
Earliest trial started Sep 30, 2021 (NCT04693598)
Timeline
2020s
- Jan 1, 2021
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
- GalactocerebrosidaseSupplementation
GALC supplementation
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT05739643 | Phase 1/Phase 2 (Phase 2) | Feb 3, 2023 | Forge Biologics, Inc |
| NCT04693598 | Phase 1/Phase 2 (Phase 2) | Sep 30, 2021 | Forge Biologics, Inc, University of Pittsburgh |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Forge Biologics, Inc | For profit | 2 | 2 | 1 | 2021 |
| University of Pittsburgh | Academic/Hospital | 1 | 0 | 1 | 2021 |
2 organizations
Page 1 / 1